阿替普酶用于发病4.5至24小时急性缺血性卒中:HOPE随机临床试验
HOPE试验在中国26家卒中中心随机纳入372例经灌注影像确认存在可挽救脑组织、发病4.5至24小时且初始未计划血管内取栓的急性缺血性卒中患者,1:1接受静脉阿替普酶0.9 mg/kg(最大90 mg)或标准药物治疗。90天改良Rankin量表0至1分(功能独立)在阿替普酶组为40%(75/186),对照组为26%(49/186),校正风险比1.52(95%CI 1.14-2.02;P=.004)。症状性颅内出血36小时内阿替普酶组3.8% vs 对照组0.51%(校正风险比7.34,95%CI 1.54-34.84;P=.01),90天全因死亡率两组均为11%(校正风险比0.91,95%CI 0.52-1.62;P=.76)。作者结论认为,在此类患者中延迟静脉阿替普酶带来功能获益,但症状性颅内出血增加。
要点
- 发病4.5至24小时、灌注影像显示可挽救脑组织且初始未计划取栓的卒中患者,阿替普酶组90天功能独立40% vs 对照组26%(校正RR 1.52,95%CI 1.14-2.02)。
- 症状性颅内出血36小时内阿替普酶组3.8% vs 标准治疗组0.51%(校正RR 7.34,95%CI 1.54-34.84)。
- 90天全因死亡率阿替普酶组11% vs 标准治疗组11%(校正RR 0.91,95%CI 0.52-1.62),无显著差异。
- 静脉阿替普酶剂量为0.9 mg/kg,最大剂量90 mg,用于发病4.5至24小时且无初始取栓计划的患者。
适用人群与场景
- 发病4.5至24小时(发病时间未知时取最后正常时间与症状识别时间的中点)就诊的急性缺血性卒中患者,经灌注影像确认存在可挽救脑组织,且初始未计划血管内取栓。
- 研究纳入年龄中位数72岁(IQR 64-80),女性160例(43%)。
诊断标准与关键阈值
- 可挽救脑组织由灌注影像识别。
- 功能独立定义为90天改良Rankin量表评分0至1分。
处置流程与药物剂量
- 阿替普酶组:静脉阿替普酶0.9 mg/kg,最大剂量90 mg。
- 对照组:标准药物治疗。
研究设计与关键结果
- 随机、开放标签、盲法终点试验,中国26家卒中中心,纳入372例,阿替普酶组186例、标准治疗组186例,全部完成试验。
- 主要疗效终点90天功能独立:阿替普酶组75/186(40%)vs 对照组49/186(26%),校正风险比1.52(95%CI 1.14-2.02;P=.004),未校正风险差13.98%(95%CI 4.50%-23.45%)。
- 安全性:36小时内症状性颅内出血阿替普酶组3.8% vs 对照组0.51%(校正风险比7.34,95%CI 1.54-34.84;P=.01;未校正风险差3.23%[0.28%-6.19%])。
- 90天全因死亡率阿替普酶组11% vs 对照组11%(校正风险比0.91,95%CI 0.52-1.62;P=.76;未校正风险差0%[95%CI -6.30%至6.30%])。
证据类型、等级与局限
- 证据类型:随机、开放标签、盲法终点临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于发病4.5至24小时、灌注影像显示可挽救脑组织且初始未计划取栓的急性缺血性卒中患者,作者结论认为静脉阿替普酶提供功能获益,尽管症状性颅内出血增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The safety and efficacy of intravenous thrombolytics beyond 4.5 hours after ischemic stroke onset remain inadequately studied.
OBJECTIVE: To evaluate the safety and efficacy of intravenous alteplase administered 4.5 to 24 hours after stroke onset in patients with salvageable brain tissue, regardless of the presence of large vessel occlusion.
DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label, blinded end-point trial was conducted at 26 stroke centers across China. A total of 372 patients with acute ischemic stroke and salvageable brain tissue identified by perfusion imaging were enrolled between June 21, 2021, and June 30, 2024 (final follow-up October 2, 2024). Eligibility criteria included stroke onset (or the midpoint between last known well and symptom recognition if onset was unknown) of 4.5 to 24 hours prior to presentation, and no initial plan for endovascular thrombectomy. Data were analyzed from December 2024 to February 2025.
INTERVENTIONS: Patients were randomly assigned (1:1) using a minimization algorithm to receive intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg; n = 186) or standard medical treatment (n = 186).
MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was functional independence, defined as a modified Rankin Scale score of 0 to 1 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage within 36 hours and all-cause mortality within 90 days.
RESULTS: Among 372 patients who were enrolled (median [IQR] age, 72 [64-80] years; 160 [43%] women), all completed the trial. The primary outcome occurred in 75 of 186 patients (40%) in the alteplase group and 49 of 186 (26%) in the control group (adjusted risk ratio, 1.52 [95% CI, 1.14-2.02]; P = .004; unadjusted risk difference, 13.98% [95% CI, 4.50%-23.45%]). The incidence of symptomatic intracranial hemorrhage was higher with alteplase at 3.8% compared with 0.51% with standard treatment (adjusted risk ratio, 7.34 [95% CI, 1.54-34.84]; P = .01; unadjusted risk difference, 3.23% [0.28%-6.19%]), and mortality was 11% in both groups (adjusted risk ratio, 0.91 [95% CI, 0.52-1.62]; P = .76; unadjusted risk difference, 0% [95% CI, -6.30% to 6.30%]).
CONCLUSIONS AND RELEVANCE: In patients with acute ischemic stroke with salvageable brain tissue identified by perfusion imaging who did not initially receive thrombectomy, intravenous alteplase administered 4.5 to 24 hours after onset provided functional benefit, despite an increase in symptomatic intracranial hemorrhage.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04879615.
参考来源
- Zhou Y, He Y, Campbell BCV, et al. Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial. JAMA. 2025. PMID: 40773205. doi:10.1001/jama.2025.12063
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。